公司概覽
業務類別 Biotechnology
業務概覽 C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
公司地址 490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
電話號碼 +1 617 231-0700
傳真號碼 --
公司網頁 https://www.c4therapeutics.com
員工數量 104
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Kendra R. Adams Chief Financial Officer and Treasurer 美元 485.00K 26/02/2026
Ms. Kelly A. Schick Chief People Officer -- 29/04/2025
Dr. Paige Mahaney, PhD Chief Scientific Officer -- 29/04/2025
Mr. Mark Mossler Chief Accounting Officer -- 26/02/2026
Mr. Scott N. Boyle, M.B.A.,PhD Chief Business Officer -- 29/04/2025
Mr. Andrew J. Hirsch Director, President and Chief Executive Officer 美元 665.00K 26/02/2026
Dr. Leonard M.J. Reyno, M.D. Chief Medical Officer 美元 572.00K 29/04/2025
Ms. Jolie M. Siegel Chief Legal Officer and Secretary -- 29/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Ronald Harold Wilfred Cooper Chairman of the Board 26/02/2026
Dr. Kenneth C. Anderson, M.D. Independent Director 26/02/2026
Dr. Laura Bessen, M.D. Independent Director 26/02/2026
Mr. Utpal Koppikar Independent Director 26/02/2026
Dr. Donna Roy Grogan, M.D. Independent Director 26/02/2026
Mr. Andrew J. Hirsch Director, President and Chief Executive Officer 26/02/2026
Dr. Stephen Fawell, PhD Independent Director 26/02/2026
Mr. Stephen L. Hoerter Independent Director 26/02/2026
Mr. Owen P. Hughes, Jr Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:14)
代號 名稱 佔比% 持有日期
IBBiShares Biotechnology ETF0.60%28/02/2026
SCHASchwab US Small-Cap ETF™0.39%28/02/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.25%27/02/2026
IWCiShares Micro-Cap ETF0.19%28/02/2026
FESMFidelity Enhanced Small Cap ETF0.16%27/02/2026
DFASDimensional US Small Cap ETF0.11%27/02/2026
AVSCAvantis US Small Cap Equity ETF0.08%28/02/2026
SCHBSchwab US Broad Market ETF™0.03%28/02/2026
QQQSInvesco NASDAQ Future Gen 200 ETF0.03%27/02/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%27/02/2026
BIBProShares Ultra Nasdaq Biotechnology0.005%27/02/2026
GUGGuggenheim Active Allocation Fund0.0005%30/11/2025
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0003%31/05/2023
DFATDimensional US Targeted Value ETF<0.000001%24/10/2025
DFAUDimensional US Core Equity Market ETF<0.000001%17/07/2025
DFUSDimensional US Equity Market ETF<0.000001%17/02/2026
HDGProShares Hedge Replication<0.000001%30/06/2025
ITOTiShares Core S&P Total US Stock Mkt ETF<0.000001%27/02/2026
ITWOProShares Russell 2000 High Income ETF<0.000001%30/06/2025
IWNiShares Russell 2000 Value ETF<0.000001%28/02/2026
 1    2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.